The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Coverage of academic research, clinical trials, and methodological developments across mental health.
Across this desk's coverage this year, CNS and psychiatric trials have repeatedly appeared as completed in registry records while their results remained publicly unavailable. That gap has a name, a legal deadline attached in some cases and none in others, and a compliance record that varies by a factor of five depending on who ran the study. None of it means a trial failed. Almost none of it means nothing.
Federal money for psychedelics went from nothing to a real portfolio in two years. It is not a copy of the company pipeline. The NIH is funding the questions private capital has structural reasons to skip.
Deuteration replaces a hydrogen atom with its heavier isotope to slow a specific step of metabolism. It is a precision pharmacokinetic tool, not a new mechanism, and it has become a favored way to re-engineer known psychiatric molecules. Here is what it does, what it has already done, and what it cannot do.
A decade of breakthroughs, advisory committee meetings, draft guidance documents, and one rejection. The agency's position has been consistent in ways the field has been slow to acknowledge, and the current voucher moment makes more sense read against the full record than against any individual moment.
The two concepts are routinely conflated, and the conflation has cost the field a decade. Why blinding fails in psychedelic trials, why expectancy is a separate and harder problem, and what trial designs actually solve for it.
An evergreen reference on what actually matters in a psychedelic-assisted therapy trial readout: blinding analyses, expectancy controls, dose-response designs, and the questions to ask before you trust the headline number.